The Influence of Chronic Renal Failure on Drug Metabolism and Transport

被引：66

作者：

Dreisbach, A. W. ^{[1
]}

机构：

[1] Univ Mississippi, Med Ctr, Dept Med, Div Nephrol, Jackson, MS 39216 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2009年 / 86卷 / 05期

关键词：

DOWN-REGULATION; HEPATIC CYTOCHROME-P450; PHARMACOKINETICS; DISEASE; HEMODIALYSIS; ERYTHROMYCIN; ACETYLATION; IMPAIRMENT; EXPRESSION; MIDAZOLAM;

D O I：

10.1038/clpt.2009.163

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Chronic renal failure (CRF) has been shown, in animal models and clinical studies, to significantly reduce nonrenal clearance and to alter the bioavailability of predominantly metabolized drugs. Phase II reactions and drug transporters such as P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) are also affected. High levels of parathyroid hormone (PTH), cytokines, and uremic toxins are implicated in some of these effects, which have a clinically significant impact on drug disposition and increase the risk of adverse drug reaction.

引用

页码：553 / 556

页数：4

共 31 条

[1]

Aronoff G.R., 2007, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, V5th

[2]

BIANCHETTI G, 1976, Clinical Pharmacokinetics, V1, P373, DOI 10.2165/00003088-197601050-00004

[3] Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis [J].

De Martin, Sara ;

Orlando, Rocco ;

Bertoli, Massimo ;

Pegoraro, Paola ;

Palatini, Pietro .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (06) :597-606

[4] Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease [J].

Dowling, TC ;

Briglia, AE ;

Fink, JC ;

Hanes, DS ;

Light, PD ;

Stackiewicz, L ;

Karyekar, CS ;

Eddington, ND ;

Weir, MR ;

Henrich, WL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) :427-434

[5]

Dreisbach AW, 2008, EXPERT OPIN DRUG MET, V4, P1065, DOI [10.1517/17425255.4.8.1065, 10.1517/17425255.4.8.1065 ]

[6] Cytochrome P4502C9 activity in end-stage renal disease [J].

Dreisbach, AW ;

Japa, S ;

Gebrekal, AB ;

Mowry, SE ;

Lertora, JJL ;

Kamath, BL ;

Rettie, AE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) :475-477

[7] Effects of uptake and efflux transporter inhibition on erythromycin breath test results [J].

Frassetto, L. A. ;

Poon, S. ;

Tsourounis, C. ;

Valera, C. ;

Benet, L. Z. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (06) :828-832

[8]

Frye Reginald F., 1996, Clinical Pharmacology and Therapeutics, V59, P155, DOI 10.1038/sj.clpt.1996.120

[9] KINETICS OF PROCAINAMIDE AND N-ACETYLPROCAINAMIDE IN RENAL-FAILURE [J].

GIBSON, TP ;

ATKINSON, AJ ;

MATUSIK, E ;

NELSON, LD ;

BRIGGS, WA .

KIDNEY INTERNATIONAL, 1977, 12 (06) :422-429

[10]

GILBERT GN, 2009, SANFORD GUIDE ANTIMI

← 1 2 3 4 →